Tumor Treating Fields (TTFields) are electric fields that disrupt cancer cell division [Science of TTFields]. TTFields may interfere with the electrically charged cellular components of cancer cells, disrupting their normal function and ultimately may lead to cell death. As a result, the cancer cell division may be slowed, or even stopped, inhibiting tumor growth.
TTFields are delivered to the body region where the tumor is located using an investigational medical device called NovoTTF-200T NovoTTF-200T is a portable, lightweight, battery-operated device designed to deliver TTFields to non-small cell lung cancer (NSCLC).
Patients receiving TTFields need to wear four adhesive patches called ILE Transducer Arrays (arrays) on their chest, which deliver the TTFields non-invasively to the lungs. The device is intended for continuous home use by patients [Living with TTFields].
NovoTTF-200T for the treatment of non-small cell lung cancer is investigational; it has not been approved by the U.S. Food and Drug Administration (FDA). The safety and effectiveness of TTFields in this condition is still unknown, and will be evaluated in this clinical study [The KEYNOTE B36 Study].
TTFields therapy has been approved for adult patients with recurrent (as a monotherapy) and newly diagnosed glioblastoma multiforme (GBM) ) (in combination with a chemotherapy called temozolomide), in the United States under the Premarket Approval (PMA) pathway, has obtained a CE mark in Europe, and is approved in Japan for the same indication. The use of TTFields concurrent with chemotherapy has also been CE marked in Europe and approved for adult patients with malignant pleural mesothelioma (MPM) under FDA’s Humanitarian Device Exemption (HDE) pathway.